Sigrid Carlsson, MD, PhD, MPH

Assistant Attending Epidemiologist

Sigrid Carlsson, MD, PhD, MPH

Assistant Attending Epidemiologist

Share
Print
Share
Print
Sigrid Carlsson, MD, PhD, MPH Assistant Attending Epidemiologist

Office Phone

646-888-8250

Dr. Carlsson’s research is focused on screening and early detection of prostate cancer. She is an investigator in the world’s largest randomized study of screening for prostate cancer, the European Randomized Study of Screening for Prostate Cancer. Dr. Carlsson’s research aims at finding a better balance between the harms and benefits of prostate-specific antigen (PSA) screening, through the use of multiplex testing and risk-stratified strategies that incorporate clinical information, biomarkers and magnetic resonance imaging. Her work on how the benefits and harms of prostate cancer screening varies by PSA levels at age 60 and how re-screening intervals can be adapted accordingly, was published in the British Medical Journal and has helped inform the screening guidelines in place at MSK as well as national guidelines. Dr. Carlsson is funded by a K22 career development award from the National Cancer Institute to study the psychology of decision making to better understand patients’ information needs, which will facilitate the development of better decision aids and lead to improved shared decision making.

Publications

Selected peer-reviewed publications:

  1. Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A, Lilja H. (2017) Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study. Eur Urol. 1, 46-52.
  2. Carlsson S, Assel M, Sjoberg D, Ulmert H, Hugosson J, Lilja H, Vickers A. (2014) Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ. 348, g2296.
  3. Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, & Hugosson J. (2012) Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol. 30, 2581-4.
  4. Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Zappa M, Tammela TL, Mäkinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ. (2012) Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 367, 595-605.
  5. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, & Lilja H. (2010) Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. Lancet Oncol. 11, 725-32.

View a full listing of Sigrid Carlsson’s journal articles.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sigrid Carlsson discloses the following relationships and financial interests:

  • AdMeTech Foundation
    Provision of Services (uncompensated)
  • American Urological Association
    Provision of Services (uncompensated)
  • Australian Prostate Centre
    Provision of Services (uncompensated)
  • BJU International
    Provision of Services
  • European Association of Urology
    Provision of Services (uncompensated)
  • Grand Rounds in Urology
    Provision of Services (uncompensated)
  • Malecare Inc.
    Provision of Services (uncompensated)
  • National Comprehensive Cancer Network
    Provision of Services (uncompensated)
  • Prevent Cancer Foundation
    Provision of Services (uncompensated)
  • Société Internationale d'Urologie (SIU)
    Provision of Services
  • The Journal of Sexual Medicine
    Provision of Services
  • World Urologic Oncology Federation
    Provision of Services (uncompensated)

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures